Results 21 to 30 of about 145,724 (263)
Myocardial fibrosis in athletes: Additional considerations [PDF]
Clinical Cardiology, 2020 [No abstract]
Łukasz A. Małek +1 more
openaire +4 more sources
Myocardial fibrosis in athletes—Current perspective [PDF]
Clinical Cardiology, 2020 AbstractSeveral previous studies suggested that prolonged and extensive physical activity might lead to increased prevalence of myocardial fibrosis in athletes. The review summarizes these studies focusing on common patterns of myocardial fibrosis observed in athletes, their potential causes and significance.
Łukasz A. Małek +1 more
openaire +3 more sources
Frontiers in Pharmacology, 2021 Background: Lcz696 (ARNI, angiotensin receptor–neprilysin inhibitor; sacubitril/valsartan) shows an inhibitory effect on fibrosis after myocardial infarction (MI). However, the underlying signaling mechanisms are poorly understood.
Jing Liu +5 more
doaj +1 more source
LifeBackground: In arterial hypertension (AH), adverse hemodynamic consequences in the left atrium (LA) are often observed. The prognostic significance of functional vs.
Artem Ovchinnikov +6 more
doaj +1 more source
EGCG Alleviates Obesity-Induced Myocardial Fibrosis in Rats by Enhancing Expression of SCN5A
Frontiers in Cardiovascular Medicine, 2022 ObjectObesity is an increase in body weight beyond the limitation of skeletal and physical requirement, as the result of an excessive accumulation of fat in the body. Obesity could increase the risk of myocardial fibrosis. (-)-Epigallocatechin-3-gallate (
Haoan Yi +10 more
doaj +1 more source
Diagnosis of Diffuse Myocardial Fibrosis [PDF]
Circulation, 1959 Diffuse myocardial fibrosis is a disease of diverse etiology; the commonest cause is coronary artery disease. Physiologically, it produces a restriction of diastolic filling and thus resembles constrictive pericarditis and endocardial fibroelastosis. Clinically, it resembles constrictive pericarditis so closely that in many patients the differential ...
C S, BURWELL, E D, ROBIN
openaire +2 more sources
Non-Ischemic Myocardial Fibrosis in End-Stage Kidney Disease Patients: A New Perspective
Kidney and Dialysis, 2023 Cardiovascular medicine, especially for ischemic heart disease, has evolved and advanced over the past two decades, leading to substantially improved outcomes for patients, even those with chronic kidney disease.
Kenji Nakata, Nobuhiko Joki
doaj +1 more source
Frontiers in Cardiovascular MedicineBackgroundSystemic inflammation is an essential pathophysiological factor of heart failure with preserved ejection fraction (HFpEF) that supports the use of statins.
Artem Ovchinnikov +8 more
doaj +1 more source
Myocardial fibrosis in stroke survivors [PDF]
International Journal of Cardiology, 2015 Stroke survivors are most likely to die of cardiac death, yet few undergo comprehensive cardiac assessment to look for reversible causes. Myocardial fibrosis (MF) is not only the hallmark of cardiomyopathy, but also a substrate for sudden cardiac death, ventricular tachyarrhythmia and heart failure.
Wong, K. +6 more
openaire +3 more sources
Cardiovascular DiabetologyBackground Clinical trials have established the prognostic benefits of sodium‒glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) and heart failure (HF) with preserved ejection fraction (HFpEF), although the ...
Artem Ovchinnikov +6 more
doaj +1 more source